A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.
Litzow
Mark R
MR
Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA. litzow.mark@mayo.edu
Lee
Sandra
S
Bennett
John M
JM
Dewald
Gordon W
GW
Gallagher
Robert E
RE
Jain
Vibha
V
Paietta
Elisabeth M
EM
Racevskis
Janis
J
Rousey
Steven R
SR
Mazza
Joseph J
JJ
Tallman
Martin S
MS
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D006801:Humans; D010087:Oxides / Q000627:therapeutic use* / Q000633:toxicity; D018579:Patient Selection; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide